Skip to main content
. 2021 Aug 19;21:436. doi: 10.1186/s12935-021-02143-z

Table 1.

Clinicopathologic features between nuclear BCL10-negative and nuclear BCL10-positive groups of patients with PDAC

Nuclear BCL10 expression
Total (N) Negative Positive p-value
Number 136 78 (57.4%) 58 (42.6%)
Age 0.837
 Median 59.0 58.0 61.0
 Range 27–82 35–82 27–76
Sex 0.102
 Men 83 (61.0%) 43 (55.1%) 40 (69.0%)
 Women 53 (39.0%) 35 (44.9%) 18 (31.0%)
Smoking 0.262
 No 87 (64.0%) 53 (67.9%) 34 (58.6%)
 Yes 49 (36/0%) 25 (32.1%) 24 (41.4%)
Alcohol 0.937
 No 98 (72.1%) 56 (71.8%) 42 (72.4%)
 Yes 38 (27.9%) 22 (28.2%) 16 (27.6%)
Stage 0.743§
 Recurrent 37 (27.2%) 23 (29.5%) 14 (24.1%)
 Stage IIIB 19 (14.0%) 9 (11.5%) 10 (17.2%)
 Stage IV 80 (58.8%) 46 (59.0%) 34 (58.6%)
Metastases 0.667§
 Peritoneal 12 (8.8%) 7 (9.0%) 5 (9.6%)
 Liver 83 (61.0%) 47 (60.2%) 36 (62.1%)
 Other sitesa 23 (16.9%) 12 (15.4%) 11 (19.0%)
 Regional LNs 18 (13.2%) 12 (15.4%) 6 (10.3%)
Chemotherapy 0.306
 Gem-alone 44 (32.4%) 28 (35.9%) 16 (27.6%)
 Gem-based 92 (67.6%) 50 (61.1%) 42 (72.4%)
Response 0.423§
 CR + PR 11 (8.1%) 6 (7.7%) 5 (8.6%)
 SD + PD 85 (62.5%) 51 (65.4%) 34 (58.6%)
 NA 40 (29.4%) 21 (26.9%) 19 (32.8%)
NF-κB expressionb  < 0.001
 Negative 58 (61.1%) 49 (84.5%) 9 (24.3%)
 Positive 37 (38.9%) 9 (15.5%) 28 (75.7%)

PDAC pancreatic ductal adenocarcinoma, N number, LNs lymph nodes, Gem gemcitabine, CR complete remission, PR partial remission, SD stable disease, PD progressive disease, NA non-analyses or difficult to assess the response

aOther sites: included extra-liver lesions, such as lung, adrenal gland metastases

bNF-κB expression was examined in tumor cells of selected 95 cases of PDAC

P values (2-sided) were calculated using the Student t test

P values (2-sided) were calculated using the Χ2 test or the Fisher exact test

§P values (2-sided) were calculated using 1-way analysis of variance